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Objective. To determine molecular epidemiology of methicillin-resistant S. aureus in Tanzania using whole genome sequencing.
Methods. DNA from 33 Staphylococcus species was recovered from subcultured archived Staphylococcus isolates. Whole genome
sequencing was performed on IlluminaMiseq using paired-end 2×250 bp protocol. Raw sequence data were analyzed using online
tools. Results. Full susceptibility to vancomycin and chloramphenicol was observed. Thirteen isolates (43.3%) resisted cefoxitin
and other antimicrobials tested. Multilocus sequence typing revealed 13 different sequence types among the 30 S. aureus isolates,
with ST-8 (𝑛 = seven, 23%) being the most common. Gene detection in S. aureus stains were as follows: mecA, 10 (33.3%); pvl, 5
(16.7%); tst, 2 (6.7%). The SNP difference among the six Tanzanian ST-8 MRSA isolates ranged from 24 to 196 SNPs and from 16 to
446 SNPs when using the USA300 FPR3757 or the USA500 2395 as a reference, respectively. The mutation rate was 1.38 × 10−11
SNPs/site/year or 1.4 × 10−6 SNPs/site/year as estimated by USA300 FPR3757 or the USA500 2395, respectively. Conclusion. S.
aureus isolates causing infections in hospitalized patients in Moshi are highly diverse and epidemiologically unrelated. Temporal
phylogenetic analysis provided better resolution on transmission and introduction of MRSA and it may be important to include
this in future routines.
1. Introduction
Staphylococcus aureus is one of the most important causes
of serious infections in humans worldwide [1]. In particular,
methicillin-resistant S. aureus (MRSA) isolates have become
common causes of infections in hospitals as well as commu-
nity settings.
For quite some time,MRSAhas been aworldwide leading
cause of nosocomial infections [2, 3]. From the 1960s to early
1970s, MRSA infections were often confined to hospitals and
healthcare facilities. During this time mostly the classical or
hospital-associated MRSA (HA-MRSA) accounted for these
infections. In the mid-1990s, a surge of MRSA infections
was reported in community settings among healthy people
who had not been in contact with hospital environments
[4]. This change was regarded as a result of introduction
of a unique MRSA strain, so-called community associated
MRSA (CA-MRSA) [5]. The ability of CA-MRSA to cause
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frequent outbreaks, with high virulence and a high rate of
dissemination to different geographical locations, has played
a major role in increasing the emergence and distribution of
staphylococcal infections globally [6].
Diagnosis of MRSA isolates has not been easy despite
the advancement in medical technology. The cefoxitin disk
diffusionmethod is a reliable test forMRSA; however it needs
to be supplemented by several other tests [7]. The emergence
of high throughput technologies such as whole genome
sequencing (WGS) promises to revolutionize today’s clinical
microbiology practices [8], increasing insight into pathogens
and hence coming up with correct diagnosis, treatment, and
controlmeasures for disease-causing pathogens [9]. Recently,
bench-top WGS has become available and proven to be a
very valuable tool in elucidating the epidemiology of bacterial
species including MRSA [10–12]. However, the technology is
currently still out of reach for clinical laboratories in devel-
oping countries [13] and deployed rarely in research setups in
these countries [14]. Recently, this technologywas introduced
at the Kilimanjaro Christian Medical Centre (KCMC) in
Moshi, Tanzania, and already during the first test run, noso-
comial transmission of Enterococcus faecalis was identified
[15].
The prevalence of MRSA infections in most African
countries seems to be relatively low [2]. However, given the
low research intensity onMRSA infections in Africa this data
should not be neglected [16]. S. aureus and MRSA infections
contribute to significant health challenges in Tanzania as
well [17–19] despite the fact that the reports are few and
hence the current prevalencemay not be indicating the actual
disease burden. It is therefore important to be able to explain
the molecular epidemiology of the clones, which are locally
circulating.Thiswill contribute to the knowledge on infection
transmission, and hence introduction of proper treatment
and control programs. Here we report on molecular epi-
demiology of S. aureus in Tanzania using WGS tools located
at KCMC. WGS was used to determine sequence types,
phylogenetic relation, and comparison to genome sequences
that were obtained from ENA (https://www.ebi.ac.uk/ena)
and NCBI. Additionally, antimicrobial resistance genes as
well as virulence factors were determined.
2. Material and Methods
2.1. Study Setting, Participants, and Sample Collection. The
current study is based on the previously conducted project
[20] at Kilimanjaro Christian Medical Centre (KCMC) ter-
tiary care hospital in North-Eastern Tanzania, from August
2013 to August 2015. The study aimed to determine the
pattern of bacterial pathogens associatedwith different health
conditions among patients who were admitted to themedical
and surgical departments of KCMC. For the study, informed
consent was obtained from 575 patients and clinical samples
were collected from these patients who were admitted to
medical and surgical wards at KCMC during the period
defined above. Demographic data of these patients were
obtained from their patient hospital files. Relevant informa-
tion was captured on designated case record forms (CRFs)
and double entered in OpenClinica (OpenClinica LLC and
collaborators, Waltham, MA, USA). Data was extracted and
exported to STATA 13 (StataCorp LP, Texas 77845, USA) for
data analyses.
2.2. Ethical Consideration. Ethical approval for the study
was obtained from National Institute for Medical Research
with Certificate number NIMR|HQ|R.8a|Vol.IX/2080 and
from Kilimanjaro Christian Medical University College with
Certificate RECC number 891.
2.3. Laboratory Methods and Data Analysis. In the previous
study, the clinical samples collected from the 575 patients dur-
ing routine clinical care were transported to themicrobiology
unit of the Kilimanjaro Clinical Research Institute (KCRI)
Biotechnology Laboratory for routine classical microbiology
processes. Both Gram negative and positive bacteria were
observed. S. aureus was the most predominant among Gram
positive isolates. Antimicrobial susceptibility testing was
performed using disk diffusion techniques as described in
the previous study [20]. All isolates from the previous study
were stored at −80∘C for whole genome sequencing (WGS).
For the current study, we recovered 30 out of 35 S. aureus
isolates upon subculturing. All 30 isolates were subjected to
molecular biology lab for DNA isolation. We also retrieved
coagulase negative staphylococci (CoNS) isolates from the
archive. However, only CoNS of clinical importance were
included in this study [21, 22]. Genomic DNA was extracted
using MasterPure Gram Positive DNA Purification Kit
Cat. No. MGP04100, Epicentre, Illumina. The quality and
quantity of genomic DNA were confirmed using Qubit
2.0 fluorometer, (Thermal Fisher Scientific, Waltham, MA,
USA). Library preparation (dual indexing) was done using
NexteraXT DNA Preparation Kit (Illumina Inc., San Diego,
CA, USA).
Whole genome sequencing of the library was completed
on Illumina Miseq using a paired-end 2 × 250 bp protocol.
2.4. Multilocus Sequence Typing (MLST), Antimicrobial Re-
sistance, and Virulence Genes. The raw reads were de novo
assembled through the assembly pipeline (version 1.0) avail-
able from the Center for Genomic Epidemiology (CGE)
(https://cge.cbs.dtu.dk/services/) which is based on theVelvet
algorithms for de novo short reads assembly [23]. The as-
sembled sequences were analyzed using bioinformatics tools
to identify MLST sequence type (MLST version 1.7) [24],
acquired antimicrobial resistance genes (ResFinder version
2.1) [25], and virulence genes (VirulenceFinder version 1.0)
[26]. All tools were available online at https://cge.cbs.dtu
.dk/services and https://www.ebi.ac.uk/ena.
2.5. Single Nucleotide Polymorphisms (SNPs) and Temporal
Bayesian Phylogenetic Trees. Phylogenetic analyses were per-
formed on 40 ST-8 S. aureus genomes. Six ST-8 S. aureus
genomes were from the current study. These were found to
harbor the mecA gene (hence MRSA) and it was therefore
important to gain better understanding of their genetic
relation. For global comparison, 34 ST-8 MRSA genomes
were retrieved from ENA and NCBI. These 34 genomes were
from five different studies [27–30]. A much larger number
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of genomes have been deposited, but we restricted the set to
only include genomes for which epidemiological information
was available. Raw sequence data of the 6 ST-8 S. aureus from
our study has been submitted to the European Nucleotide
Archive (https://www.ebi.ac.uk/ena) under study accession
number PRJEB23314. Information pertaining to all 40 ST-
8 MRSA used for construction of phylogenetic trees in this
study is reported in the supplementary information (SI)
appendix, Tables 1a and 1b.
2.5.1. Single Nucleotide Polymorphisms. SNPs were identi-
fied using the CSI phylogeny [31, 32] pipeline, available
on CGE (http://www.genomicepidemiology.org). The raw
reads were mapped to two reference genomes, S. aureus
USA300 FPR3757 (accession number CP000255, chromo-
some length 2,917,469 bp) andUSA500 2395 (accession num-
ber CP007499, chromosomal length 2,955,646) using BWA
version 0.7.2 [33]. The mpileup tool from SAMTools version
0.1.18 [34] was applied to determine SNPs. SNPs were filtered
out when not matching the following criteria: (1) a minimum
distance of 10 bp between SNPs, (2) a minimum of 10% of the
read depth at SNP positions, (3) mapping quality above 25,
and (4) SNP quality above 30. All indels were excluded. The
SNPs from each genome were concatenated to single align-
ment corresponding to position on the reference genome.
The concatenated sequences were used for constructing a
maximum likelihood tree using FastTree [35].
2.5.2. Temporal Bayesian Phylogenetic Tree. Prior to recon-
structing a phylogenetic tree in BEAST, concatenated SNPs
were examined for significant recombination sites. We used
a novel hidden Markov model tool, RecHMM [36], to detect
clusters of sequence diversity thatmark recombination events
within branches. SNPs in these regions were excluded in the
temporal phylogenetic analysis. SNP sequences were then
used for reconstructing a temporal phylogenetic tree using
Bayesian Evolutionary Analysis Sampling Trees (BEAST)
version 1.8.3 [37] to estimate mutation rate and divergence
time. Test models with combinations of different population
size change and molecular clock were evaluated to identify
the best-fit model. This was achieved by performing different
BEAST runs with different selected models. Comparison
of the log files from all models in the output runs was
done in Tracer, a program that compares all BEAST runs
and gives a score (ACT score). The temporal tree with the
highest posterior probability was then constructed using the
best-fit model (random local clock and coalescent Bayesian
skyline). The BEAST MCMC chains were simulated for 300
million steps and subsampled every 10,000 steps. The final
maximum clade credibility (MCC) was determined using
TreeAnnotator [37] with 10% of the MCMC steps discarded
as burn-in. Statistical confidence was represented by the 95%
highest posterior density (HPD) interval. Mutation rate and
divergence timewere estimated byBEASTand the population
size over time was estimated using the Bayesian skyline plot
implemented in Tracer [37].The effective population size was
inferred by the product of the interval size (𝛾
𝑖
) and 𝑖(𝑖 − 1)/2,
where 𝑖 is the number of genealogical lineages in the interval
[38, 39].
4
2
3
2
1
2 2
11 11
7
1
2
1
2
Sequence type distribution
ST
-1
ST
-1
5
ST
-1
52
ST
-1
84
7
ST
-1
88
ST
-2
2
ST
-2
39
ST
-3
0
ST
-5
ST
-5
80
ST
-6
ST
-8
ST
-9
7
U
nk
no
w
n-
ST
ST
-n
ot
 d
et
er
m
in
ed
ST
-5
9
Figure 1: Distribution of sequence types (ST) among Staphylococ-
cus aureus and coagulase negative Staphylococcus species (CoNS).
Fourteen different sequence types were identified, with sequence
type 8 being the most common. ST-59 and undetermined ST were
observed among the CoNS (presented in red).
3. Results
3.1. Isolates Characteristics. Thirty S. aureus and three coag-
ulase negative staphylococci (CoNS) isolates from patients
who were admitted to wards of medical and surgical depart-
ments were whole genome sequenced. Of the thirty S. aureus
isolates 8, 14, and 8 were isolated in 2013, 2014, and 2015,
respectively. The three CoNS isolates were all isolated in
year 2015. Twenty-nine bacterial isolates were recovered from
wound swabs, 3 isolates from blood culture, and 1 from
sputum.The causes of thewoundswere as diverse as indicated
in Table 1.
3.2. Phenotypic Antimicrobial Resistance Pattern of S. aureus
Isolates. All S. aureus tested were susceptible to vancomycin
and chloramphenicol.Thirteen (43.3%) isolates were resistant
to cefoxitin while resistance to trimethoprim-sulfa, ery-
thromycin, and penicillin was observed for 16 (53.3%), 14
(46.7%), and 30 (100%) isolates, respectively, Table 2.
3.3. Multilocus Sequence Typing (MLST), Antimicrobial and
Virulence Genes. In silico multilocus sequence typing re-
vealed 13 different sequence types (ST) among the thirty S.
aureus isolates. There were seven S. aureus isolates (23.3%)
with ST-8, four (13.3%) with ST-1, and three (10%) with ST-
152. The remaining isolates had diverse sequence types (see
Figure 1).
The three CoNS were one S. epidermidis with ST-59 and
two S. haemolyticus of undetermined sequence type.
Presence of mecA was established in 13 (39.4%) of all
Staphylococcus spp. isolates involved in this study. Ten (33.3%)
of the thirty S. aureus isolates found to harbor mecA, thus
classified as MRSA. Six out of the ten S. aureus isolates with
mecAwere ST-8, twowere ST-239, and the remaining twohad
unknown sequence types. All threeCoNSpossessed themecA
gene as well. Additionally, five S. aureus isolates (16.7%) were
found to harbor Panton-Valentine Leukocidin (pvl) virulence
genes with absence of mecA. Two (6.7%) were found to have
tst genes for toxic shock syndrome. Other antimicrobial and
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Table 1: Isolate characteristics.
Sample name Species Collection date Diagnosis Specimen Ward Roomnumber
Bed
number
29 B S. aureus August 1, 2013 Surgery (laparotomy) Wound swab Surgical ICU 17 3
32 S. aureus August 1, 2013 Bedsore Wound swab Surgical II Corr 4
37 B S. aureus August 2, 2013 Injury-femur fracture Wound Swab Surgical II 8 3
38 S. aureus August 2, 2013 Bedsores Wound swab Surgical II 8 2
56 S. aureus August 13, 2013 Asthma + HIV Blood Medical I 2 4
59 S. aureus August 15, 2013 Tumor wound Wound swab Surgical I Corr 5
69 S S. aureus August 19, 2013 Burn wound Wound swab Surgical I 1 4
71 S. aureus August 20, 2013 Abscess Wound swab Medical I 2 2
108 S. aureus February 7, 2014 Pleural effusion (fever) Blood Medical II 11 3
143 A S. aureus March 11, 2014 Surgery (liver cirrhosis) Wound swab Medical I 5 6
153 C S. aureus March 17, 2014 Diabetes mellitus Wound swab Medical I 5 9
159 A S. aureus March 20, 2014 Abdominal tumor Wound swab Medical I 5 10
166 S. aureus March 24, 2014 MTA Wound swab Surgical I Corr -
176 A S. aureus March 31, 2014 Diabetes mellitus Wound swab Medical I 5 Extra bed
196 S. aureus April 11, 2014 Cellulitis Wound swab Surgical I 5 3
201 A S. aureus April 11, 2014 HIV (coughing) Sputum Medical I 2 Extra bed
204 S. aureus April 15, 2014 Septicemia Blood Medical ICU - 4
224 C S. aureus April 30, 2014 Diabetes mellitus Wound swab Medical II Corr 6
260 S. aureus June 2, 2014 Diabetes mellitus Wound swab Surgical I 5 8
309 B S. aureus September 19, 2014 Cellulitis Wound swab Surgical I 5 6
319 D S. aureus September 30, 2014 Burn Wound swab Surgical I 1 3
323 B S. aureus October 1, 2014 Diabetes mellitus Wound swab Surgical I Corr 5
348 B S. aureus November 18, 2014 Tropical ulcer Wound swab Surgical I 5 6
349 A S. aureus November 19, 2014 Burn wound Wound swab Surgical I 1 1
437 C S. aureus March 10, 2015 Diabetes mellitus Wound swab Surgical I 5 7
449 S. aureus March 31, 2015 Diabetes mellitus Wound swab Medical I 2 1
463 B S. aureus April 19, 2015 Surgery (laparotomy) Wound swab Surgical I 5 2
494 S. aureus May 19, 2015 Burn wound Wound swab Surgical I 1 1
547 S. epidermidis July 6, 2015 Septic wound Wound swab Surgical I 5 4
562 S. haemolyticus July 15, 2015 HIV (cough) Sputum Medical I 2 1
564 S. haemolyticus July 16, 2015 Diabetes mellitus Wound swab Surgical I 5 3
567 A S. aureus July 23, 2015 Septic wound Wound swab Surgical 1 Corr 5
577 S. aureus August 3, 2015 Diabetes mellitus Wound swab Surgical I 2 Extra bed
virulence genes possessed by all isolates are further described
in Table 3.
3.4. Single Nucleotide Polymorphisms (SNPs). Themapping of
the raw reads of these 40 genomes to the reference genome, S.
aureus USA300 FPR3757, detected 3,511 qualified SNPs. The
maximum likelihood SNP tree was constructed using these
3,511 SNPs (Figure 2(a)). RecHMM detected 353 significant
recombination SNPs. The remaining SNPs (𝑛 = 3,148,
90%) were used to construct a temporal phylogenetic tree
(Figure 2(b)).
Mapping the 40 genomes to the second reference genome,
S. aureus USA500 2395, detected 3,385 qualified SNPs.
RecHMM detected 356 significant recombination SNPs. The
maximum likelihood SNP tree was constructed using these
3385 SNPs (Figure 3(a)). The remaining SNPs (𝑛 = 3,029,
89%) were used to construct a temporal phylogenetic tree
(Figure 3(b)). From the SNP phylogenetic trees, it seems
that the six Tanzanian isolates form their own clade and are
closely clustered together. The SNP difference among the six
Tanzanian MRSA isolates ranged from 24 to 196 SNPs when
using the USA300 FPR3757 as a reference, whereas with
the USA500 2395 reference SNP differences ranged between
16 and 446 SNPs. However, the tree topology of the two
SNP phylogenetic trees remains basically unchanged. Further
information of the SNP differences among all genomes used
in construction of the phylogenetic trees is indicated in
supplementary material Tables 1a and 1b.
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Table 2: Phenotypic antimicrobial pattern of the 30 S. aureus isolates.
PATIENT ID ORG CTX C E P SXT VA
WGS 029 B S. aureus R S R R R S
WGS 032 S. aureus R S R R R S
WGS 037 B S. aureus S S S R S S
WGS 038 S. aureus S S I R S S
WGS 056 S. aureus R S R R R S
WGS 059 S. aureus S S R R I S
WGS 069 S. aureus R S R R R S
WGS 071 S. aureus R S R R R S
WGS 108 S. aureus R S R R R S
WGS 143 A S. aureus R S S R S S
WGS 153 C S. aureus R S S R R S
WGS 159 A S. aureus S S S R S S
WGS 166 S. aureus S S S R S S
WGS 176 A S. aureus S S S R S S
WGS 196 S. aureus S S R R R S
WGS 201 A S. aureus S S I R S S
WGS 204 S. aureus S I I R S S
WGS 224 C S. aureus S S S R S S
WGS 260 S. aureus S S S R S S
WGS 309 B S. aureus R S R R R S
WGS 319 D S. aureus R S R R R S
WGS 323 A S. aureus S S R R S S
WGS 348 B S. aureus R S R R R S
WGS 349 A S. aureus R S S R R S
WGS 437 S. aureus S S S R S S
WGS 449 S. aureus S S S R S S
WGS 463 B S. aureus S S S R R S
WGS 494 S. aureus R S R R R S
WGS 567A S. aureus S S S R R S
WGS 577 S. aureus S S R R R S
% resistance 𝑛 (%) 13 (43.3) 0 (0) 14 (46.7) 30 (100) 16 (53.3) 0 (0)
C: Chloramphenicol, SXT: trimeth/sulfa, CXT: cefoxitin, E: erythromycin, P: penicillin G, VA: vancomycin, R: resistance, S: susceptible, and I: intermediate.
3.5. Temporal Bayesian Phylogenetic Trees. The temporal
Bayesian phylogenetic tree using USA300 FPR3757 esti-
mated the emergence of the most recent common ancestor
to be in ∼1942. Primarily the tree is divided into two main
clusters in ∼1954 (minor) and in ∼1969 (major). The minor
cluster shows less branching until ∼1971 where two other
clusters appear, one cluster composing the Tanzanian isolates
and the other the USA500 isolate. Further evolution took
place to form another lineage in ∼2009 when the most recent
common ancestor of Tanzanian MRSA isolates seemed to
emerge. Subsequent lineages further emerged in ∼2010, 2011,
and 2012 among Tanzanian MRSA isolates. The 1969 major
cluster is more complex compared to the minor cluster. From
1969 further evolution took place in ∼1989 and in ∼1994.
However, from the tree it is predicted thatmost of the lineages
that evolved in the USA and Switzerland emerged around
1990s (Figure 1a in supplementary material).
Using USA500 2395 as the reference, the tree estimates
that the most recent common ancestor emerged around
∼1960. The tree is also divided into two major clusters in
∼1965 (major cluster) and ∼2009 (minor). The major cluster
is further divided to form subsequent lineages. In ∼1992 this
major cluster was divided into two other clusters forming
in ∼2001 and ∼2002. The 2001 cluster is mainly composed
of USA strains and few from Switzerland, while the 2002
cluster contains only Switzerland strains. The minor (2009)
lineage is composed of Tanzanian strains only, which shows
introduction of new strains in early and late ∼2011 and there-
after further evolution in ∼2012 (Figure 1b in supplementary
material). However, the infection observed in the hospital in
2013 was due to strains evolved in early and late ∼2011 while
2014 infections was due to strains evolved in both 2011 and
2012. Bayesian analysis also shows that the common ances-
tor between Tanzanian isolates and USA500 2395 emerged
around 1971, while with USA300 FPR3757 this emerged
around 1961. The mutation rates estimated from the BEAST
were 1.38×10−11 SNPs/site/year and 1.4×10−6 SNPs/site/year
using USA300 and USA500 as references, respectively.
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Figure 2: (a)Maximum likelihood SNP phylogenetic tree of forty ST-8 S. aureus genomes. Raw reads from genomes were mapped to a reference
genomeof Staphylococcus aureusUSA300 FPR3757 (accession numberCP000255, chromosome length 2,917,469 bp) to generate 3511 qualified
SNPs. SNPs generated from each genome were concatenated to single alignment corresponding to position of the reference genome. The
concatenated sequences were used for constructing a maximum likelihood tree using FastTree. The tree was visualized by using FigTree
version 1.4.0. Of the forty genomes, 6 were from Tanzania (TZ) presented in red; 23 from United States (USA) presented in blue; 6 from
Switzerland (CH) presented in pink; one from Japan (JP), Denmark (DK), and Australia (AU) presented in magenta, green, and orange,
respectively. USA500 2395 strain genome was included and presented in aqua blue. (b) Bayesian temporal phylogenetic tree of the 40 MRSA
genomes from Tanzania (TZ), United States (USA), Switzerland (CH), Japan (JP), Australia (AU), and Denmark (DK). A total of 3148 (90%)
SNP sequences were used for reconstructing Bayesian temporal phylogenetic tree using Bayesian Evolutionary Analysis Sampling Trees
(BEAST) version 1.8.3. USA300 FPR3757 (accession number CP000255, chromosome length 2,917,469 bp) was used as reference during SNP
generation. The mutation rate estimated by BEAST was 1.32 × 10−11 SNPs/site/year.
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Figure 3: (a)Maximum likelihood SNP phylogenetic tree of forty ST-8 S. aureus genomes. Raw reads from genomes were mapped to a reference
genome of Staphylococcus aureus USA500 2395 (accession number CP007499, chromosomal length 2,955,646) to generate 3385 qualified
SNPs. SNPs generated from each genome were concatenated to single alignment corresponding to position of the reference genome. The
concatenated sequences were used for constructing a maximum likelihood tree using FastTree. The tree was visualized by using FigTree
version 1.4.0. Of the forty genomes, 6 were from Tanzania (TZ) presented in red; 23 from United States (USA) presented in blue; 6 from
Switzerland (CH) presented in pink; one from Japan (JP), Denmark (DK), and Australia (AU) presented in purple, green, and orange,
respectively. USA300 FPR3757 strain genome was included and presented in aqua blue. (b) Bayesian temporal phylogenetic tree of the 40
MRSA genomes fromTanzania (Red), USA (Blue), Switzerland (CH), Japan (JP), Australia (AU), andDenmark (DK). A total of 3029 (89%) SNP
sequences were used for reconstructing Bayesian temporal phylogenetic tree using Bayesian Evolutionary Analysis Sampling Trees (BEAST)
version 1.8.3. Staphylococcus aureusUSA500 2395 (accession numberCP007499, chromosomal length 2,955,646)was used as reference during
SNP generation. The mutation rate estimated by BEAST was 1.4 × 10−6 SNPs/site/year.
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4. Discussion
S. aureus is an important causative agent of hospital-associat-
ed infections worldwide. Studying the pathogen at its molec-
ular level has the potential to bring about breakthroughs in
diagnosis, treatment, and infection control. In the current
studywe determined themolecular epidemiology of S. aureus
isolates using the next generation whole genome sequencing
facility available at KCMC-KCRI Biotechnology Laboratory
in Moshi, Tanzania.
Multilocus sequence typing revealed 13 different sequence
types among the 30 S. aureus isolates. This diversity suggests
that S. aureus infections in the hospitalized patients that were
sampled were not epidemiologically related. This is in line
with similar findings in other studies in Africa [40] and other
parts of the world [41].The high genetic diversity of S. aureus
lineages confers their high adaptability to different environ-
ments resulting in widespread distribution [42]. Sequence
type 8MRSAwhich has been observed to be the predominant
strain in our hospital is also considered to be themost studied
CA-MRSA [43]. The strain has been observed in other parts
of the world [44–46] as a cause of infections in both hospital
and community settings [43].
Resistance of S. aureus to the antimicrobial agent cefoxitin
can be used to predict existence of MRSA [47]. This study
reports resistance to cefoxitin to be 43.3% by using clas-
sical microbiology techniques. The prevalence was further
narrowed down to 33.3% when detecting mecA using whole
genome sequencing.These findings are not far fromwhat has
been reported in other studies in Tanzania, as it seems that
the prevalence of MRSA in Tanzania is above 10% but less
than 50% [17–19, 48–51] in hospitalized patients and ranges
between 1.5% and 2.1% in healthy individuals [19, 52]. The
prevalence of MRSA infections observed in most African
countries ranges between 25% and 50% [2], which is lower
than what is seen on other continents [53].
Several virulence genes including pvl and tst were
observed in the isolates studied. Some of these genes may
have influenced the severity of the S. aureus infections. It
then becomes necessary to properly identify the genes for the
purpose of controlling and monitoring their spread. In our
study we reported five isolates identified to carry pvl genes
with one of them also possessing the tst gene. All five isolates
weremethicillin susceptible S. aureus. Such findings correlate
with other studies, which indicate that approximately 50% of
MSSA isolates from Africa carry pvl genes [54]. However the
findings are in contrast with a study conducted in Tanzania
whereby ST-88 and ST-1797 were found to be dominant
MRSA clones, and pvl genes were detected in ST-88 MRSA
isolates [50].
Regarding determination of antimicrobial resistance and
virulence genes in S. aureus, tracing genetic relation of clones
circulating in a certain locality is vital key for determining
the evolution history [55]. Phylogenetic analysis additionally
provides insight into the current and possible future compo-
sition of the organism’s population.The phylogenetic analysis
of ST-8 strains from Tanzania using two different references
clearly demonstrated that they belong to their own clade in
global epidemiology.The twomaximum likelihood SNP trees
did not differ significantly in topology.However, the temporal
phylogenetic analysis suggests that theUSA500 2395 is closer
related to Tanzanian ST-8 MRSA than USA300 FPR3757
despite the fact that these two strains are closely related [28].
The temporal phylogenetic analysis based on the USA500-
2395 reference suggests that the MRSA infection observed
at KCMC hospital was due to multiple introduction events.
Three strains emerged at the beginning and end of ∼2011;
two caused infection in 2013, and one stayed without causing
infection in that year. The third together with the one
emerged in 2012 caused infections in 2014.
These results illustrate the value of temporal phylogeny in
phylogenetic analysis. It provides a framework for examining
evolution and molecular diversity in a more comprehensive
way, by suggesting approximate times at which divergence
occurred. However, the analysis is computationally expen-
sive, taking several days.
5. Conclusion
This study showed that S. aureus isolates causing infections in
hospitalized patients in Moshi, Tanzania, are highly diverse
and likely not epidemiologically related. Using temporal
phylogenetic analysis provided a higher resolution insight
into the transmission and introduction of MRSA, and it may
be valuable to include this analysis in future routine analyses
despite its computational cost. This study demonstrates the
feasibility and value of high throughput technologies in a
resource-constrained setting. We propose that technologies
such as NGS should be deployed in particular in infectious
disease-endemic settings. This will improve diagnosis, treat-
ment, and control of infections in these areas. Just as most
of Africa skipped land-line telephony to jump straight to
ubiquitous mobile phone use, next generation sequencing
technology may provide a similar leapfrog in infectious
disease diagnosis, treatment, and control.
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